Stem cell therapy improves condition of patients with type 2 diabetes

06/19/2014 | Australian Life Scientist

Type 2 diabetes patients who were treated with infusions of Mesoblast's mesenchymal precursor cells had greater reductions in blood sugar levels than those who received a placebo, according to a study presented at a meeting of the American Diabetes Association. The 61-patient midstage trial found that the cells were well-tolerated and that treatment was associated with a dose-dependent improvement in glycemic control.

View Full Article in:

Australian Life Scientist

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
Washington DC, DC
Director, Corporate Counsel
Tarrytown, NY